Acute myeloid leukemia: epidemiology and etiology, Cancer, vol.107, pp.2099-107, 2006. ,
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B, Blood, vol.58, pp.1203-1215, 1981. ,
Adult acute myeloid leukaemia: update on treatment, Med J Aust, vol.170, pp.39-43, 1999. ,
Acute myeloid leukaemia, Lancet, vol.368, pp.1894-907, 2006. ,
Drug therapy for acute myeloid leukemia, Blood, vol.106, pp.1154-63, 2005. ,
Induction therapy in acute myeloid leukemia: intensifying and targeting the approach, Curr Opin Hematol, vol.17, pp.79-84, 2010. ,
Anthracycline dose intensification in acute myeloid leukemia, N Engl J Med, vol.361, pp.1249-59, 2009. ,
Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives, Haematologica, vol.93, pp.1769-72, 2008. ,
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates, Cancer Res, vol.71, pp.6300-6309, 2011. ,
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibodycalicheamicin conjugate for treatment of acute myeloid leukemia, Bioconjug Chem, vol.13, pp.47-58, 2002. ,
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin, Clin Cancer Res, vol.17, pp.6417-6444, 2011. ,
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, Lancet, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01056520
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association, Am J Hematol, vol.87, pp.62-67, 2012. ,
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group, Leukemia, vol.21, pp.66-71, 2007. ,
A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells, ChemMedChem, vol.6, pp.1006-1016, 2011. ,
Design of selfimmolative linkers for tumour-activated prodrug therapy, Anticancer Agents Med Chem, vol.8, pp.618-655, 2008. ,
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, Anal Biochem, vol.338, pp.284-93, 2005. ,
Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia, Cancer, vol.85, pp.348-57, 1999. ,
Synthesis and antitumor efficacy of a beta-glucuronidase-responsive albumin-binding prodrug of doxorubicin, J Med Chem, vol.55, pp.4516-4536, 2012. ,
ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells, Neoplasia, vol.11, pp.157-66, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00416521
Robust quantification of in vitro angiogenesis through image analysis, IEEE Trans Med Imag, vol.24, pp.549-53, 2005. ,
Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells, Cancer Res, vol.67, pp.8708-8723, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00416414
Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks), Br J Pharmacol, vol.159, pp.93-101, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00561579
Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid, Blood, vol.100, pp.594-602, 2002. ,
ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes, Am J Physiol Heart Circ Physiol, vol.295, pp.1956-65, 2008. ,
Folate-targeted therapies for cancer, J Med Chem, vol.53, pp.6811-6835, 2010. ,
New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents, Hematology Am Soc Hematol Educ Program, pp.143-50, 2005. ,
Folate-targeted drug strategies for the treatment of cancer, Curr Opin Investig Drugs, vol.9, pp.1277-86, 2008. ,
Folate-targeted chemotherapy, Adv Drug Deliv Rev, vol.56, pp.1127-1168, 2004. ,
Targeting therapeutic and imaging agents to folate receptor positive tumors, Curr Pharm Biotechnol, vol.6, pp.131-50, 2005. ,
Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Adv Drug Deliv Rev, vol.56, pp.1067-84, 2004. ,
Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy, Am J Physiol Cell Physiol, vol.287, pp.517-543, 2004. ,
Folate receptor-mediated drug targeting: from therapeutics to diagnostics, J Pharm Sci, vol.94, pp.2135-2181, 2005. ,
Discovery and development of folic-acidbased receptor targeting for imaging and therapy of cancer and inflammatory diseases, Acc Chem Res, vol.41, pp.120-129, 2008. ,
Folate-targeted therapeutic and imaging agents for cancer, Curr Opin Chem Biol, vol.13, pp.256-62, 2009. ,
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate, Cancer Res, vol.67, pp.6376-82, 2007. ,
Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies, Bioconjug Chem, vol.21, pp.5-13, 2010. ,
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors, J Clin Oncol, vol.18, pp.2282-92, 2000. ,
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice, J Pharmacol Exp Ther, vol.308, pp.1073-82, 2004. ,
The first génération of ?-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy, Angewandte Chemie, vol.51, pp.11606-11616, 2012. ,